Xiang, MA
Andrew Xiang, Littleton, MA US
Patent application number | Description | Published |
---|---|---|
20100277732 | SPECTROMETERS WITH ABERRATION-CORRECTED CONCAVE DIFFRACTION GRATINGS AND TRANSMISSIVE ABERRATION CORRECTORS - The invention generally relates to spectrometers and optical systems useful therein. More particularly, the invention generally relates to optical systems and systems having improved functionalities, flexibilities, and design options. For example, optical systems of the invention employ an aberration-corrected concave grating along with one or more transmissive aberration correctors. | 11-04-2010 |
Jason Shaoyun Xiang, Winchester, MA US
Patent application number | Description | Published |
---|---|---|
20080311113 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE - The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5. | 12-18-2008 |
20100010012 | GLUTAMATE AGGRECANASE INHIBITORS - The present invention relates to modulators of metalloproteinase activity. | 01-14-2010 |
20100029648 | 11-Beta HSD1 Inhibitors - This invention relates to inhibiting 11βHSD1. | 02-04-2010 |
20100137298 | Biaryl Sulfonamides and Methods for Using Same - The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors. | 06-03-2010 |
Jie Xiang, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20090004852 | Nanostructures Containing Metal Semiconductor Compounds - A network element ( | 01-01-2009 |
Jing Xiang, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20100278045 | METHOD FOR MAINTAINING DIFFERENTIATED SERVICES DATA FLOW AT A NETWORK DEVICE IMPLEMENTING REDUNDANT PACKET DISCARD SECURITY TECHNIQUES - An improved method is described for providing Differentiated Services (Diffserv) traffic to a node in a network that implements a security method that discards duplicate packets received at the node. The method includes the step of identifying at least two service levels to be provided to received traffic and assigning different size look-back window counts to each of the service levels. The look-back window count indicates a number of packets that have been previously received at the node that should be compared against a received packet to determine whether a duplicate packet has been received. In one embodiment, a service level that has higher priority is assigned a lower look-back window count and thus examines fewer previously received packets than a service level having a lower priority. Such an arrangement reduces the possibility that traffic having higher priority is dropped as a security measure. | 11-04-2010 |
20140269316 | METHOD FOR MAINTAINING DIFFERENTIATED SERVICES DATA FLOW AT A NETWORK DEVICE IMPLEMENTING REDUNDANT PACKET DISCARD SECURITY TECHNIQUES - An improved method is described for providing Differentiated Services (Diffserv) traffic to a node in a network that implements a security method that discards duplicate packets received at the node. The method includes the step of identifying at least two service levels to be provided to received traffic and assigning different size look-back window counts to each of the service levels. The look-back window count indicates a number of packets that have been previously received at the node that should be compared against a received packet to determine whether a duplicate packet has been received. In one embodiment, a service level that has higher priority is assigned a lower look-back window count and thus examines fewer previously received packets than a service level having a lower priority. Such an arrangement reduces the possibility that traffic having higher priority is dropped as a security measure. | 09-18-2014 |
Lian-Qin Xiang, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20100277732 | SPECTROMETERS WITH ABERRATION-CORRECTED CONCAVE DIFFRACTION GRATINGS AND TRANSMISSIVE ABERRATION CORRECTORS - The invention generally relates to spectrometers and optical systems useful therein. More particularly, the invention generally relates to optical systems and systems having improved functionalities, flexibilities, and design options. For example, optical systems of the invention employ an aberration-corrected concave grating along with one or more transmissive aberration correctors. | 11-04-2010 |
Shi-Hua Xiang, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20090110690 | Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens - The present disclosure relates to stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, to crystalline forms of the stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, and to the high resolution structure obtained from these crystals by X-ray diffraction methods. Methods for identifying immunogenic polypeptides based on these structures are also disclosed. | 04-30-2009 |
20090191235 | CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS AND TRIGGERING HIV-1 ENVELOPE TO REVEAL CRYPTIC V3-LOOP EPITOPES - Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed. | 07-30-2009 |
20120034255 | CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS - Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed. | 02-09-2012 |
20120328641 | CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS - Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed. | 12-27-2012 |
Shuanglin Xiang, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20090123426 | Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer off cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells. | 05-14-2009 |
20120093773 | Compositions for Bacterial Mediated Gene Silencing and Methods of Using Same - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer of cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells. | 04-19-2012 |
Tao Xiang, Worcester, MA US
Patent application number | Description | Published |
---|---|---|
20090202557 | Compositions and methods for crystallizing antibody fragments - The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes. | 08-13-2009 |
Yibin Xiang, Waltham, MA US
Patent application number | Description | Published |
---|---|---|
20100261668 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE - Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1). | 10-14-2010 |
Yibin Xiang, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20110184021 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors - A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. | 07-28-2011 |
20110275673 | INHIBITORS OF SPHINGOSINE KINASE 1 - The invention relates to compounds of Formula (I). Compounds of the present invention are inhibitors of sphingosine kinase 3, and are useful in the treatment of various disorders and conditions, such as inflammatory disorders. | 11-10-2011 |
20120232063 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria - The present invention relates to methods of treating a subject with malaria comprising administering a 2-aminoindole compound represented by Formula: (I)—The values and preferred values of the variables in Structural Formula I are defined herein. | 09-13-2012 |
20120322786 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): | 12-20-2012 |
20120322787 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - A compound is represented by Structural Formula (I): | 12-20-2012 |
Yibin Xiang, Dracut, MA US
Patent application number | Description | Published |
---|---|---|
20140255381 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | 09-11-2014 |
20140371460 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | 12-18-2014 |